Japan Ministry Selects Thomson Reuters Data For Strategic National Project On Accelerating Translational Research In The Application Of Basic Research To Patient Care
Thomson Reuters Information Solutions Will Be Used In MEXT-Funded Project Involving Nine Universities and Research Institute Over Three Years
Tokyo, Japan — The Scientific business of Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals, announced today that its key intellectual property and pharmaceutical & life sciences data platforms, Thomson InnovationSM, Thomson Pharma® and IDRAC®, have been selected by the Foundation for Biomedical Research and Innovation (FBRI) for a major national project that aims to accelerate translational research from academic research to clinical research and enhanced clinical care for the greater benefit of patients in Japan.
The national project entitled “Coordination, Support and Training Program for Translational Research” (visit http://www.tr.mext.go.jp) will be funded over three years by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. The project fund, in turn, was allocated by the Japan Science & Technology Agency (JST) in support of the government’s decade-long basic science and technology policy to bridge academic research and industrial expertise on applying basic research into practical clinical outcomes that can widely benefit patients in terms of improved medical care.
The national translational research project involves nine universities and a research institute, namely Tohoku University, University of Tokyo, Kyoto University, Osaka University, Kyushu University, Hokkaido Organization for Translation Research which comprises Hokkaido University, Asahikawa Medical College Medical College, Sapporo Medical University, and FBRI.
Said Professor Masanori Fukushima, Director of Translational Research Information Center, FBRI and Director of Translational Research Center, Kyoto University Hospital, “Our basic research in life sciences in Japan has been widely published in major scientific journals and is highly regarded by the international community. However, the results of basic research have not been sufficiently translated yet into clinical practice such as medicine and drug manufacturing so that the public can benefit from this translational research. This national translational research project is of great significance as we are now actively leveraging on our academic research and the expertise and market knowledge of our industrial partners in our long-standing alliance to accelerate the development of basic research into clinical trials and enable the public to benefit from improved medical care. Hence, it is critical that we rely on data and information we can trust, which is why we chose Thomson Reuters for its global source of information of integrity for professionals and businesses. We strongly encourage Japanese universities and institutions to learn and proactively make use of these databases for their research. This will help in our implementation of translational research which will better facilitate drug discovery and development in Japan.”
Said Mr. Masaki Nagao, managing director of the Japan Regional Business Unit, Scientific business of Thomson Reuters, “We are pleased and honoured to be selected as part of this important national project that demonstrates Japan’s strong commitment to translating basic research undertaken by Japanese universities and institutions into applications of enhanced clinical care that can be implemented on a national scale to benefit the wider population.
With Thomson Innovation and Thomson Pharma, researchers and professionals benefit from the only integrated information products in the market that are able to provide them with the most complete data resource for prior art and competitive intelligence research, as well as comprehensive global pharmaceutical information that covers the entire drug discovery and development pipeline and field of life sciences. IDRAC is a single, complete resource for the latest regulatory information in markets all around the world, particularly useful in regulatory science which is now being implemented in Japan. Ultimately, our information and solutions aim to help researchers and companies make better decisions faster.”
In November 2008, the Thomson Innovation user interface was launched in Japanese to enhance productivity and decision making for Japanese intellectual property (IP) professionals. Japan remains the worldwide leader in published patents according to data analysis of Derwent World Patent Index®, the world’s most comprehensive database of enhanced patent documents. Thomson Innovation was recognized by R&D Magazine as one of the top 100 most technologically significant products in 2008.
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.